(BBWI) Bath & Body Works - Overview

Sector: Consumer Cyclical | Industry: Specialty Retail | Exchange: NYSE (USA) | Market Cap: 3.973m USD | Total Return: -47.9% in 12m

Body Care, Candles, Hand Soaps, Fragrances, Sanitizers
Total Rating 50
Safety 57
Buy Signal -0.68
Specialty Retail
Industry Rotation: -2.5
Market Cap: 3.97B
Avg Turnover: 103M
Risk 3d forecast
Volatility52.5%
VaR 5th Pctl8.69%
VaR vs Median0.54%
Reward TTM
Sharpe Ratio-0.98
Rel. Str. IBD3.6
Rel. Str. Peer Group10
Character TTM
Beta1.553
Beta Downside2.138
Hurst Exponent0.456
Drawdowns 3y
Max DD69.98%
CAGR/Max DD-0.30
CAGR/Mean DD-0.66
EPS (Earnings per Share) EPS (Earnings per Share) of BBWI over the last years for every Quarter: "2021-04": 1.25, "2021-07": 1.34, "2021-10": 0.92, "2022-01": 2.3, "2022-04": 0.64, "2022-07": 0.52, "2022-10": 0.4, "2023-01": 1.86, "2023-04": 0.35, "2023-07": 0.4, "2023-10": 0.48, "2024-01": 2.06, "2024-04": 0.38, "2024-07": 0.37, "2024-10": 0.49, "2025-01": 2.09, "2025-04": 0.49, "2025-07": 0.37, "2025-10": 0.35, "2026-01": 2.05,
EPS CAGR: 36.40%
EPS Trend: 10.4%
Last SUE: 3.65
Qual. Beats: 1
Revenue Revenue of BBWI over the last years for every Quarter: 2021-04: 1470, 2021-07: 1704, 2021-10: 1681, 2022-01: 3028, 2022-04: 1450, 2022-07: 1618, 2022-10: 1604, 2023-01: 2888, 2023-04: 1396, 2023-07: 1559, 2023-10: 1562, 2024-01: 2912, 2024-04: 1384, 2024-07: 1526, 2024-10: 1610, 2025-01: 2787, 2025-04: 1424, 2025-07: 1549, 2025-10: 1594, 2026-01: 2724,
Rev. CAGR: 18.31%
Rev. Trend: 16.7%
Last SUE: 3.18
Qual. Beats: 1

Warnings

Altman Z'' 0.98 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: BBWI Bath & Body Works

Bath & Body Works Inc. (BBWI) is a specialty retailer focused on personal care and home fragrance products. Its portfolio includes candles, soaps, body lotions, and sanitizers sold under its namesake brand. Following its 2021 separation from L Brands, the company operates a multi-channel model consisting of company-owned stores in the U.S. and Canada, e-commerce platforms, and international franchise partnerships.

The specialty retail sector for personal care is characterized by high inventory turnover and seasonal demand cycles, particularly during the fourth quarter. Bath & Body Works maintains a vertically integrated supply chain, with the majority of its products manufactured in North America to ensure faster speed-to-market for seasonal collections. For a deeper look at these operational metrics, you may find ValueRays detailed reports helpful. The company is headquartered in Columbus, Ohio, and has maintained a market presence since 1963.

Headlines to Watch Out For
  • Direct-to-consumer digital sales growth offsets declining physical store foot traffic
  • Raw material cost volatility impacts gross margins for home fragrance products
  • International franchise expansion drives high-margin royalty revenue in emerging markets
  • Seasonal consumer spending patterns during holiday quarters dictate annual earnings performance
  • Product innovation cycles in personal care categories sustain brand loyalty and pricing power
Piotroski VR‑10 (Strict) 8.0
Net Income: 649.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.17 > 0.02 and ΔFCF/TA 3.52 > 1.0
NWC/Revenue: 5.87% < 20% (prev 8.10%; Δ -2.23% < -1%)
CFO/TA 0.22 > 3% & CFO 1.10b > Net Income 649.0m
Net Debt (4.00b) to EBITDA (1.40b): 2.85 < 3
Current Ratio: 1.27 > 1.5 & < 3
Outstanding Shares: last quarter (211.6m) vs 12m ago -2.48% < -2%
Gross Margin: 43.73% > 18% (prev 0.44%; Δ 4.33k% > 0.5%)
Asset Turnover: 146.7% > 50% (prev 150.0%; Δ -3.29% > 0%)
Interest Coverage Ratio: 4.17 > 6 (EBITDA TTM 1.40b / Interest Expense TTM 276.0m)
Altman Z'' 0.98
A: 0.08 (Total Current Assets 2.02b - Total Current Liabilities 1.59b) / Total Assets 5.07b
B: -0.28 (Retained Earnings -1.44b / Total Assets 5.07b)
C: 0.23 (EBIT TTM 1.15b / Avg Total Assets 4.97b)
D: -0.20 (Book Value of Equity -1.25b / Total Liabilities 6.35b)
Altman-Z'' Score: 0.98 = BB
Beneish M -3.23
DSRI: 0.88 (Receivables 180.0m/205.0m, Revenue 7.29b/7.31b)
GMI: 1.01 (GM 43.73% / 44.25%)
AQI: 0.97 (AQ_t 0.19 / AQ_t-1 0.20)
SGI: 1.00 (Revenue 7.29b / 7.31b)
TATA: -0.09 (NI 649.0m - CFO 1.10b) / TA 5.07b)
Beneish M-Score: -3.23 (Cap -4..+1) = AA
What is the price of BBWI shares? As of May 16, 2026, the stock is trading at USD 17.09 with a total of 5,303,990 shares traded.
Over the past week, the price has changed by -13.38%, over one month by -4.74%, over three months by -30.15% and over the past year by -47.88%.
Is BBWI a buy, sell or hold? Bath & Body Works has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy BBWI.
  • StrongBuy: 7
  • Buy: 4
  • Hold: 8
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the BBWI price?
Analysts Target Price 27.6 61.6%
Bath & Body Works (BBWI) - Fundamental Data Overview as of 11 May 2026
P/E Trailing = 6.3441
P/E Forward = 7.5301
P/S = 0.545
P/B = 1403.3759
P/EG = 0.8656
Revenue TTM = 7.29b USD
EBIT TTM = 1.15b USD
EBITDA TTM = 1.40b USD
Long Term Debt = 3.61b USD (from longTermDebt, last quarter)
Short Term Debt = 475.0m USD (from shortTermDebt, last quarter)
Debt = 4.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.00b USD (from netDebt column, last quarter)
Enterprise Value = 7.97b USD (3.97b + Debt 4.95b - CCE 953.0m)
Interest Coverage Ratio = 4.17 (Ebit TTM 1.15b / Interest Expense TTM 276.0m)
EV/FCF = 9.22x (Enterprise Value 7.97b / FCF TTM 865.0m)
FCF Yield = 10.85% (FCF TTM 865.0m / Enterprise Value 7.97b)
FCF Margin = 11.86% (FCF TTM 865.0m / Revenue TTM 7.29b)
Net Margin = 8.90% (Net Income TTM 649.0m / Revenue TTM 7.29b)
Gross Margin = 43.73% ((Revenue TTM 7.29b - Cost of Revenue TTM 4.10b) / Revenue TTM)
Gross Margin QoQ = 45.67% (prev 41.28%)
Tobins Q-Ratio = 1.57 (Enterprise Value 7.97b / Total Assets 5.07b)
Interest Expense / Debt = 1.39% (Interest Expense 69.0m / Debt 4.95b)
Taxrate = 25.09% (135.0m / 538.0m)
NOPAT = 861.4m (EBIT 1.15b * (1 - 25.09%))
Current Ratio = 1.27 (Total Current Assets 2.02b / Total Current Liabilities 1.59b)
 Debt / Equity = -3.87 (negative equity) (Debt 4.95b / totalStockholderEquity, last quarter -1.28b)
 Debt / EBITDA = 2.85 (Net Debt 4.00b / EBITDA 1.40b)
Debt / FCF = 4.63 (Net Debt 4.00b / FCF TTM 865.0m)
Total Stockholder Equity = -1.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.06% (Net Income 649.0m / Total Assets 5.07b)
 RoE = -44.22% (negative equity) (Net Income TTM 649.0m / Total Stockholder Equity -1.47b)
 RoCE = 53.63% (EBIT 1.15b / Capital Employed (Equity -1.47b + L.T.Debt 3.61b))
RoIC = 35.59% (NOPAT 861.4m / Invested Capital 2.42b)
WACC = 5.68% (E(3.97b)/V(8.93b) * Re(11.45%) + D(4.95b)/V(8.93b) * Rd(1.39%) * (1-Tc(0.25)))
Discount Rate = 11.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -1.70%
[DCF] Terminal Value 86.15% ; FCFF base≈783.0m ; Y1≈768.3m ; Y5≈784.8m
[DCF] Fair Price = 96.19 (EV 23.37b - Net Debt 4.00b = Equity 19.37b / Shares 201.4m; r=6.0% [WACC]; 5y FCF grow -2.82% → 3.0% )
EPS Correlation: 10.35 | EPS CAGR: 36.40% | SUE: 3.65 | # QB: 1
Revenue Correlation: 16.73 | Revenue CAGR: 18.31% | SUE: 3.18 | # QB: 1
EPS current Quarter (2026-07-31): EPS=0.20 | Chg30d=-6.57% | Revisions=-14% | Analysts=15
EPS current Year (2027-01-31): EPS=2.63 | Chg30d=+1.10% | Revisions=+25% | GrowthEPS=-18.0% | GrowthRev=-2.9%
EPS next Year (2028-01-31): EPS=2.87 | Chg30d=+2.50% | Revisions=+29% | GrowthEPS=+9.0% | GrowthRev=+2.2%
[Analyst] Revisions Ratio: +29%